PPA
FDMT icon

Parametric Portfolio Associates’s 4D Molecular Therapeutics FDMT Stock Holding History

Parametric Portfolio Associates’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$611K Buy
40,381
+3,431
+9% +$53.9K ﹤0.01% 3002
2021
Q4 		$811K Sell
36,950
-5,582
-13% -$137K ﹤0.01% 2866
2021
Q3 		$1.15M Buy
42,532
+10,374
+32% +$296K ﹤0.01% 2742
2021
Q2 		$774K Buy
32,158
+685
+2% +$21K ﹤0.01% 2887
2021
Q1 		$1.36M Sell
31,473
-2,971
-9% -$132K ﹤0.01% 3008
2020
Q4 		$1.43M Buy
+34,444
New +$1.42M ﹤0.01% 2861

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Parametric Portfolio Associates's FDMT Position: Q1 2022 in Review

Parametric Portfolio Associates increased its 4D Molecular Therapeutics (FDMT) stake by 9.3% in Q1 2022, buying an estimated $53.9K and bringing the position to 40,381 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #3002.

Parametric Portfolio Associates first reported a position in FDMT in Q4 2020 and has held it in 6 quarters since. The position peaked at $1.43M in Q4 2020. 80 funds tracked by Wall St. Rank hold FDMT as of Q1 2022.

  • Parametric Portfolio Associates held 40,381 shares of 4D Molecular Therapeutics worth $611K as of Q1 2022.
  • Parametric Portfolio Associates bought 3,431 4D Molecular Therapeutics shares in Q1 2022, an estimated $53.9K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3002 holding.
  • Parametric Portfolio Associates first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 6 quarters since.
  • Parametric Portfolio Associates's 4D Molecular Therapeutics position peaked at $1.43M in Q4 2020.
  • 80 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.